Abstract
Alzheimers disease is a progressive, neurodegenerative disorder characterized by a devastating cognitive decline. The disease is identified pathologically by amyloid plaques composed of aggregated amyloid-β peptide, neurofibrillary tangles composed of aggregated, hyperphosphorylated tau protein and neuron loss. While the disease was first described in 1906, transgenic mouse models for the study of Alzheimers disease pathologies have only been available to scientists for fifteen years. Despite the generation of many different mouse models that develop amyloid plaques or neurofibrillary tangles, it has only been in recent years that mouse models demonstrating the two pathologies together have been made. Also, neuron loss has been difficult to achieve in many models. Most recently, several transgenic mouse lines have been generated that do demonstrate all three pathological characteristics of Alzheimers disease: amyloid plaques, neurofibrillary tangles and neuron loss. This review will focus on the advances made in our understanding of Alzheimers disease pathology using the transgenic mouse models. It will also discuss the limitations associated with studying some of these mice and how transgenic mouse models have contributed to the development of therapeutics for the treatment of Alzheimers disease.
Keywords: Alzheimer's disease, transgenic, amyloid, neurofibrillary tangles, neurodegeneration, amyloid precursor protein
CNS & Neurological Disorders - Drug Targets
Title: The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
Volume: 9 Issue: 4
Author(s): Donna M. Wilcock
Affiliation:
Keywords: Alzheimer's disease, transgenic, amyloid, neurofibrillary tangles, neurodegeneration, amyloid precursor protein
Abstract: Alzheimers disease is a progressive, neurodegenerative disorder characterized by a devastating cognitive decline. The disease is identified pathologically by amyloid plaques composed of aggregated amyloid-β peptide, neurofibrillary tangles composed of aggregated, hyperphosphorylated tau protein and neuron loss. While the disease was first described in 1906, transgenic mouse models for the study of Alzheimers disease pathologies have only been available to scientists for fifteen years. Despite the generation of many different mouse models that develop amyloid plaques or neurofibrillary tangles, it has only been in recent years that mouse models demonstrating the two pathologies together have been made. Also, neuron loss has been difficult to achieve in many models. Most recently, several transgenic mouse lines have been generated that do demonstrate all three pathological characteristics of Alzheimers disease: amyloid plaques, neurofibrillary tangles and neuron loss. This review will focus on the advances made in our understanding of Alzheimers disease pathology using the transgenic mouse models. It will also discuss the limitations associated with studying some of these mice and how transgenic mouse models have contributed to the development of therapeutics for the treatment of Alzheimers disease.
Export Options
About this article
Cite this article as:
M. Wilcock Donna, The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (4) . https://dx.doi.org/10.2174/187152710791556168
DOI https://dx.doi.org/10.2174/187152710791556168 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stroke-Induced Neurogenesis: Physiopathology and Mechanisms
Current Neurovascular Research Editorial (Thematic Issue: Multi-Target Drug Discovery in Medicinal Chemistry: Current Status and Future Perspectives)
Mini-Reviews in Medicinal Chemistry Omega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Metabolic Stress and Inflammation: Implication in Treatment for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Tau as a Molecular Marker of Development, Aging and Neurodegenerative Disorders
Current Aging Science Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials Targeting Parkinson’s - Tyrosine Hydroxylase and Oxidative Stress as Points of Interventions
CNS & Neurological Disorders - Drug Targets β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry Avoidance of Aβ[25-35] / (H2O2) -Induced Apoptosis in Lymphocytes by the Cannabinoid Agonists CP55, 940 and JWH-015 via Receptor-Independent and PI3K-Dependent Mechanisms: Role of NF- κB and p53
Medicinal Chemistry Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry APP Transgenic Mouse Models and their Use in Drug Discovery to Evaluate Amyloid-β Lowering Therapeutics
CNS & Neurological Disorders - Drug Targets Coumarins: Auspicious Cholinesterase and Monoamine Oxidase Inhibitors
Current Topics in Medicinal Chemistry Cell Microencapsulation Implants into the Central Nervous System
Recent Patents on Nanomedicine